Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

Table 2 Efficacy analysis

Variables	PD-1 inhibitors plus chemoradiotherapy (N = 40)
Overall response at 3 months post radiotherapy
Objective response rate	70.0% (95%CI 55.8% to 84.2%)
Disease control rate	100% (95%CI 100% to 100%)
Progression-free survival (PFS)
Median PFS, months	9 (95% CI 3.1 to 14.9)
PFS rate at 6 months	75.5% (95% CI 62.2% to 88.8%)
PFS rate at 12 months	41.4% (95% CI 26.1% to 56.7%)
Overall survival (OS)
Median OS, months	19 (95% CI 6.3 to 31.7)
OS rate at 6 months	87.7% (95% CI 77.5% to 97.9%)
OS rate at 12 months	72.8% (95% CI 59.0% to 86.6%)
OS rate at 24 months	33.3% (95% CI 18.7% to 47.9%)

ISSN: 1748-717X